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Abstract
Background: Endoscopically defined mucosal healing in Crohn’s disease is associated with improved outcomes.
Panenteric capsule endoscopy enables a single non-invasive assessment of small and large bowel mucosal inflammation.
Aims and methods: This multicentre observational study of patients with suspected and established Crohn’s dis-
ease examined the feasibility, safety and impact on patient outcomes of panenteric capsule endoscopy in routine
clinical practice. The potential role in assessment of disease severity and extent by a comparison with existing
clinical and biochemical markers is examined.
Results: Panenteric capsule endoscopy was performed on 93 patients (71 with established and 22 with suspected
Crohn’s disease). A complete examination occurred in 85% (79/93). Two cases (2.8%) of capsule retention occurred
in patients with established Crohn’s disease. Panenteric capsule resulted in management change in 38.7% (36/93)
patients, including 64.6% (32/48) of those with an established diagnosis whose disease was active, and all three
patients with newly diagnosed Crohn’s disease. Montreal classification was upstaged in 33.8% of patients with
established Crohn’s disease and mucosal healing was demonstrated in 15.5%. Proximal small bowel disease
upstaged disease in 12.7% and predicted escalation of therapy (odds ratio 40.3, 95% confidence interval 3.6–
450.2). Raised C-reactive protein and faecal calprotectin were poorly sensitive in detecting active disease (0.48 and
0.59 respectively).
Conclusions: Panenteric capsule endoscopy was feasible in routine practice and the ability to detect proximal
small bowel disease may allow better estimation of prognosis and guide treatment intensification. Panenteric
capsule endoscopy may be a suitable non-invasive endoscopic investigation in determining disease activity and
supporting management decisions.
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Key Summary
Summarise the established knowledge on this subject
• Biochemical and clinical markers poorly predict active disease and need for treatment escalation;
• Panenteric capsule endoscope is feasible, safe and has the potential to non-invasively assess patients with
Crohn’s Disease.
What are the significant and/or new findings of this study?
• Panenteric capsule endoscope can upstage disease in one-third of patients with a threefold increase in the
identification of proximal small bowel disease;
• Identification of proximal small bowel disease predicted treatment intensification.
Introduction
Endoscopically defined mucosal healing is associated
with a reduced need for steroid treatment, hospitalisa-
tion and surgery in patients with Crohn’s disease.
Therefore, investigation by ileocolonoscopy is recom-
mended in those with suspected Crohn’s disease and in
those with established disease who need reassessment.1
Ileal disease is associated with complicated disease
phenotypes and the Inflammatory Bowel Disease
Genetics Consortium suggests that the association of
jejunal disease with stricturing and multiple surgeries is
greater still.2 Therefore guidelines also recommend rou-
tine small bowel assessment in patients with new diag-
noses of Crohn’s disease in order to assess prognosis.1
Historically this has involved radiological imaging,
which is less sensitive than capsule endoscopy in
identifying early mucosal disease, particularly in the
jejunum.3–5 Capsule endoscopy is more acceptable to
patients than conventional endoscopy.6,7 Capsule
retention occurs in 1.5% of those with suspected, and
213% with established, Crohn’s disease, although can
be minimised by excluding those known to have stric-
tures or following the failure of passage of a patency
device.1
The PillCam Crohn’s (Medtronic, Dublin, Ireland)
is a novel panenteric capsule endoscope (PCE) devel-
oped to identify inflammatory activity in both small
and large bowel. It has cameras at both ends and
acquires up to 35 frames per second depending on tran-
sit speed (Figure 1(a)).8,9 The platform provides a facil-
ity to localise and grade disease activity and quantify
extent as well as compare successive examinations to
allow assessment of disease progression and response
to therapy (Figure 1(b)). Feasibility studies have sug-
gested that the panenteric capsule is safe and has a
greater diagnostic yield than ileocolonoscopy; however,
effect on management decisions and correlation with
biochemical markers of disease in adult patients has
not been studied.8,10
Objectives
The impact of PCE in clinical practice was investigated.
The feasibility, safety and effect of a panenteric capsule
examination on defining patients’ disease phenotype
was studied by: i) examining completion and capsule
retention rates, ii) the effect of panenteric capsule on
escalation or de-escalation of treatment, iii) comparing
the extent of disease (Montreal classification) before
and after examination, and iv) comparing disease activ-
ity assessed by capsule endoscopy with clinical and bio-
chemical markers of activity.
Methods
Six centres were involved in the study: Sheffield
Teaching Hospitals and South Tyneside NHS
Foundation Trusts (UK), Sheba Medical Centre
(Ramat Gan, Israel), Mater Dei Hospital (Msida,
Malta) Ospedale Maggiore Policlinico (Milan, Italy)
and Complejo Hospitalario de Navarra (Pamplona,
Spain). Capsule endoscopy was performed at the dis-
cretion of the clinician after consultation with the
patient as part of routine practice. Ileocolonoscopy
and small bowel radiology or PCE were discussed
with patients with established Crohn’s or symptoms
which the referring clinician suspected as possibly
being due to Crohn’s disease. Patients who preferred
capsule endoscopy were included in the study.
Data collected from patients’ case records undergo-
ing PCE between July 2017 and May 2019 included
age, sex, disease duration, medication history, indica-
tion, blood test parameters, faecal calprotectin (FCP),
Harvey Bradshaw Index and Montreal classification.
Blood tests and FCP were requested in the month
prior to capsule endoscopy. A C-reactive protein
(CRP) of greater than 5 mg/L and FCP of over
200mg/kg were considered to be elevated.
PCE was performed according to the protocols
of individual units based on previous published
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experience.8,9 The PillCam Crohn’s platform includes a
software reporting system which divides the gastrointes-
tinal tract into small bowel tertiles (SB1, 2 and 3: accord-
ing to time and speed of capsule transit) and colon, so
that inflammation in each region can be graded (with a
score of 1–3) according to ulcer size and depth. The
reader records the most common (MCL) and most
severe lesion (MSL) in each region and the extent (as a
percentage) of the region involved. In addition, an activ-
ity score previously designed and validated for small
bowel capsule endoscopy, the Lewis score, can also be
assigned following small bowel assessment.11
Disease phenotype was assessed using the Montreal
classification (ileal, L1; colonic, L2; ileocolonic, L3 and
proximal small bowel disease, L4 – defined on Capsule
endoscopy (CE) as disease in the first and second tertiles).
Active disease was defined as the presence of at least mild
ulceration (MCL 1) affecting at least 10% of the segment
or the presence of moderate or severe ulceration (MSL 2
or 3) of any extent. An upstage in disease classification
was considered if L1 or L2 progressed to L3 disease, or if
L4 disease was identified in addition, or if B1 (inflamma-
tory) progressed to B2 (stricturing) disease.
A comprehensive formal report was provided for
referring clinicians who had sole responsibility for ther-
apeutic interventions. Effect on patient outcomes was
determined by reviewing management decisions made
at the post-capsule endoscopy consultation between cli-
nician and patient.
Continuous and categorical variables are reported as
mean ( standard error of mean) and frequency (%)
respectively. Differences in groups are compared using
independent Student t-test and chi squared tests (sig-
nificance level p<0.05). Logistic regression is used to
determine associations between clinical, biochemical
and endoscopic measures of disease activity, with esca-
lation of therapy. The performance of CRP and FCP in
the prediction of disease activity is reported as area
under the receiver operating characteristic curve
(AUROCC), sensitivity and specificities.
Ethical considerations
The service evaluation involved patients seen as part of
routine clinical practice. All identifiable medical infor-
mation was removed and all analyses performed using
anonymised data. The data collection was in line with
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Figure 1. (a) PillCam Crohn’s capsule, DR3 data recorder and wireless sensors. (b) A representative graphic of a patient with
active Montreal L3 B2 disease and images of small bowel (SB) lesions (c and d), SB stricture (e) and colonic lesion (f). RAPIDTM
Reader Software breaks down small bowel and colonic segments based on identified anatomical landmarks. The reader
classifies the most severe and most common lesion (none, mild, moderate and severe), presence or absence of stricture and
extent of disease (0–10%, 10–30%, 30–60%, 60–100% of segment).
Tai et al. 3
good clinical practice policies and with the General
Data Protection Regulation UE 2016/679.
Results
PCE was performed in 22 patients with suspected, and
71 patients with established, Crohn’s disease, mean age
36.6 (1.39) years, 36.6% male. Of those with estab-
lished Crohn’s disease, PCE was performed in 58
(81.7%) to assess symptoms, in 12 (16.9%) to assess
response to treatment after symptomatic remission and
in one (1.4%) to assess the post-operative risk of dis-
ease recurrence. The median time between last disease
reassessment and PCE was 23 (interquartile range 36)
months (Table 1).
Disease activity and extent
Active disease was present in 48 of 71 (67.6%) of those
with established and three of 22 (13.6%) of those with
suspected Crohn’s disease. Two of three new cases were
confirmed histologically. Active disease was seen in
41 of 58 (70.7%) of symptomatic patients and seven
of 13 (53.8%) asymptomatic patients with established
Crohn’s disease (p¼ 0.24). Mean Lewis score was 923
(169) and 321 (197) respectively for patients with
Crohn’s disease with and without symptoms
(p¼ 0.09). Figure 1(c) and (d) shows images of active
disease.
Disease extent was upstaged in 24 of 71 (33.8%)
patients. This included patients with upper gastrointes-
tinal or proximal small bowel disease (L4 notification)
which increased from five (7.0%) to 14 (19.7%,
p<0.05) following panenteric examination. This repre-
sents 24.1% of symptomatic patients who had more
proximal small bowel involvement than asymptomatic
patients (24.1% vs. 0%, p¼ 0.05). Disease extent was
downstaged in 19 of 71 (26.8%) patients where exam-
ination demonstrated complete mucosal healing in 12
of 71 (16.9%) patients, and in the remaining 29 of 71
(40.8%) disease classification remained unchanged
(Table 2).
Comparison with non-invasive markers
Patients with active disease had a higher mean CRP
(11.4 21.2 vs. 4.0 9.2, p¼ 0.003), FCP (812 145.8
vs. 55.8 21.1, p¼ 0.02) and Harvey Bradshaw Index
(5.0 0.49 vs. 4.2 0.88, p¼ 0.02) than patients with
inactive disease. Active disease was associated with
a raised CRP level (odds ratio (OR) 11.6, 95%
confidence interval (CI) 3.1–43.3) and FCP (OR 3.5,
95% CI 1.1–10.9) but not with changes in Harvey
Bradshaw Index.
CRP and FCP results were available in 89% and
60% of cases. CRP and FCP had an AUROCC of
0.73 (95% CI 0.58–0.87) and 0.75 (95% CI 0.60–0.90)
respectively. CRP levels above 5 mg/L had 48% sensi-
tivity and 85% specificity in detecting active disease
identified by PCE in patients known to have Crohn’s
disease, of whom 23 patients (47%) had values
within normal range. Patients with active disease had
FCP levels less than 50mg/kg in four (14%), between
50mg/kg and 200mg/kg in nine (31%) and
over 200mg/kg in 16 (55%). FCP levels of greater
than 200mg/kg had a 59% sensitivity and 65% specif-
icity in detecting active disease.
Table 2. Extent of suspected Crohn’s disease before and after
investigation based on Montreal classification.
Before capsule
n (%)
After capsule
n (%)
No disease – 12 (16.9)
L1 34 (47.9) 26 (36.6)
L2 7 (9.9) 7 (9.9)
L3 29 (40.8) 25 (35.2)
þL4 5 (7.0)a 14 (19.7)
B1 54 (76.1) 38 (53.5)
B2 13 (18.3) 17 (23.9)
B3 4 (5.6) –
aOne patient had only proximal small bowel L4 disease.
Table 1. Investigations prior to panenteric capsule
endoscopy.
n (%)
Suspected Crohn’s disease 22 (23.7)
Previous endoscopy
Complete colonoscopy 10 (45.5)
Incomplete colonoscopy 6 (27.3)
No previous endoscopy 6 (27.3)
Established Crohn’s disease 71 (76.3)
Previous investigations
Ileocolonoscopy 51 (71.8)
Colonoscopy 11 (15.5)
CE 19 (26.8)
MRI 30 (42.3)
CTE 16 (22.5)
BaFT 3 (4.2)
Colonoscopy alone 22 (30.1)
Colonoscopy and SB investigations 19 (26.8)
SB investigations alone 28 (39.4)
Unknown 2 (2.8)
Had treatment between last assessment
and panenteric capsule
endoscopy n,(%) Yes
30 (42.3)
Biologics 20 (28.2)
Immunomodulators 14 (19.7)
Surgery 1 (1.4)
CE: Capsule endoscopy ; MRI: magnetic resonance imaging; CTE:
Computed Tomography Enterography; BaFT: Barium Follow Through.
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Change in management
Management was changed in 36 (38.7%): 33 of 71
(46.5%) with established Crohn’s and all three patients
in whom a new diagnosis was made. Overall, 32 of 48
(64.6%) patients with an established diagnosis of
Crohn’s whose disease was active had a change in
drug therapy. This included a step up in treatment
comprising the addition or class change of biologics
in 24.6%, the addition of immunomodulators and ste-
roids in 15.5% and 5.6% respectively. Endoscopic
stricture dilatation occurred in two cases (when
retained capsules were also removed). Of the remaining
16 of the 48 patients with active disease, 10 were con-
tinued on the same biological or immunomodulator
therapy, three were offered further treatment but
opted for observation only and complete follow-up
data could not be obtained for three patients. The pres-
ence of proximal small bowel involvement and moder-
ate to severe small bowel disease (a Lewis score of over
790) increased the likelihood of therapy escalation
(Table 3). De-escalation of biologics occurred follow-
ing a normal examination.
Completeness of examinations
Complete small bowel and colon examination was
achieved in 94.6% (88/93) and 84.9% (79/93) respec-
tively. Eighty-eight (94.6%) patients had a patency
examination or small bowel imaging (68/71 established,
20/22 suspected) prior to examination. In three with
established and two with suspected Crohn’s disease,
no imaging or patency evaluation was performed.
Incomplete examinations included two capsule reten-
tions, amounting to 2.8% (2/71) of patients with estab-
lished Crohn’s disease. Capsule retentions occurred
behind one small bowel and one colonic stricture,
both of which were treated with endoscopic stricture
dilatation and capsule retrieval. In eight patients
(8.6%) where the colon was incompletely examined
(excluding a colonic stricture), five were due to loss of
battery power, two due to loss of capsule signal (2.2%)
and one, inadequate bowel preparation (1.1%).
Discussion
Active Crohn’s disease identified by PCE was not reli-
ably predicted by symptoms, Harvey Bradshaw Index
or biochemical markers. The panenteric examination
upstaged the Montreal classification in one-third of
patients with a threefold increase in a diagnosis of an
L4 phenotype which predicted treatment intensifica-
tion. PCE provided a complete, single test, small and
large bowel assessment in 84.9% of patients. There was
a 2.8% capsule retention rate in patients known to have
Crohn’s disease and both were subsequently removed
endoscopically following stricture dilatation.
Management was changed overall in 39%, in 47% of
those with established disease and in 65% of patients
with Crohn’s disease who had symptoms.
A more advanced Montreal classification in one-
third of patients with Crohn’s disease is not unexpected
in a population which included symptomatic patients,
but PCE increased the recognition of L4 disease three-
fold, which is consistent with that of Leighton et al.,
who showed that PCE detected additional disease
proximal to the terminal ileum in 45% of 66 adult
patients.8 Evidence that proximal bowel disease is a
poor prognostic factor would explain the association
with therapy escalation demonstrated.2
CRP, FCP level, but not Harvey Bradshaw Index
predicted escalation in therapy. A raised CRP >5mg/L
was moderately specific (85%) and FCP >200mg/kg less
Table 3. Predictors of escalation of drug therapy in all patients undergoing panenteric capsule endoscopy.
No escalation
n (%)
Drug escalation
n (%) Odds ratio 95% CI
Raised Harvey Bradshaw Index, >6 20 (35.7) 17 (45.9) 1.5 0.66–3.57
Raised C-reactive protein, >5 mg/L 9 (18.8) 20 (57.1) 5.8 2.2–15.5
Raised faecal calprotectin, >200 mg/L 10 (28.6) 13 (61.9) 4.1 1.3–12.8
Lewis score
0–135 30 (53.6) 9 (24.3) Reference –
135–790 18 (32.1) 12 (32.4) 1.6 0.5–5.0
>790 8 (14.3) 16 (43.2) 3.4 1.0–12.1
Disease location
No disease 11 (28.9) 2 (6.1) Reference –
L1 13 (34.2) 7 (21.2) 4.7 0.49–45.2
L2 2 (5.3) 4 (12.1) 22.0 1.5–314.3
L3 8 (21.1) 10 (30.3) 15.1 1.6–142.2
þL4 4 (10.5) 10 (30.3) 40.3 3.6–450.2
CI: confidence interval.
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so (65%) in the diagnosis of active Crohn’s disease.
These findings are consistent with the demonstration of
better mucosal healing in the tight control arm of the
CALM study, which used both biomarkers as part of a
protocol to signal the need for escalation of therapy.12
However, the disappointing sensitivities in detecting
activity suggest that this approach might miss patients
who could benefit from further treatment. Previous stud-
ies have also found that CRP and FCP are poor predic-
tors of disease activity and should not be used alone as
surrogate markers for mucosal healing.13,14 The Harvey
Bradshaw Index did not correlate with findings. This is
unsurprising given that clinical scores do not correlate
with endoscopic activity.15,16
Historically, patients having a panenteric examina-
tion undergo both small bowel radiology or capsule
endoscopy, and ileocolonoscopy. Studies comparing
diagnostic accuracy of PCE against ileocolonoscopy
and magnetic resonance enterography (MRE) are
pending. If we assume that MRE would identify any
small bowel disease and that ileocolonoscopy would
identify any ileocolonic disease, ileocolonoscopy
would have identified active Crohn’s disease in
97.6%, although this would fall to 46.3% if ileal intu-
bation were unsuccessful. A small bowel examination
in addition would therefore be necessary to identify the
remaining patients with active disease. Of 41 patients
with active disease, 53 segments of active disease were
observed. Colonoscopy alone, ileocolonoscopy alone
and MRE alone would have missed 64.2% (34/53),
30.2% (16/53) and 35.8% (19/53) of segments with
active disease. Therefore, if presence of proximal
small bowel disease helps prognostication and manage-
ment, up to one-third may be incompletely assessed
with ileocolonoscopy alone. These scenarios are likely
to be an underestimate. Although Crohn’s disease has
a predilection towards the terminal ileum, in reality
ileocolonoscopy does not examine the whole distal
small bowel tertile as was assumed. Nevertheless, it is
possible that repeating conventional investigations
might have demonstrated the same upstage in disease
classification; however, PCE is a single test (rather than
separate small and large bowel assessments) and radi-
ology appears less sensitive in recognising uncomplicat-
ed L4 disease.3,17
Shorter intervals between endoscopic assessments
are associated with better outcomes.18 However, in a
comparison of acceptability of tests, patients with
inflammatory bowel disease (IBD) found flexible
endoscopy6 and MRE19 less acceptable than capsule
endoscopy. Furthermore, Ferreira et al. calculated a
12.7% lifetime risk of serious endoscopic adverse
events in patients with IBD in a time prior to the
‘treat to target’ era, after which more frequent assess-
ment is likely to increase rates of complications.20
Capsule endoscopy may therefore offer a safer, as
well as more acceptable, approach to the assessment
of mucosal healing.
Studies which associate proximal disease with poor
prognosis are based on radiological imaging and there-
fore the association might be with more advanced dis-
ease, rather than uncomplicated mucosal disease
detected by capsule endoscopy. However, recent evi-
dence suggests that jejunal lesions identified using cap-
sule endoscopy appear to increase the risk of disease
recurrence21 and a high small bowel capsule endoscopy
disease activity score predicts both short- and long-
term disease exacerbations.11,22 Furthermore, mucosal
disease detected by PCE used to monitor response to
treatment intensification in a ‘treat to target’ strategy
has been shown to achieve mucosal healing in
children.9
The experience of capsule retention behind small
and large bowel strictures in this study is the first
reported with PCE: no retentions occurred in the 66
patients examined by Leighton et al., nor in a paediat-
ric study.8,9 In the first capsule retention in our study,
no patency device was administered; however, a MRE
showed non-stricturing distal ileitis. In the second case
of retention, the capsule was retained behind a colonic
stricture following a patency capsule test. A positive
radiofrequency signal 30 h post-ingestion of the
device was followed by a targeted computed tomogra-
phy (CT)23 which revealed that it was in the ascending
colon and correctly concluded that there was no small
bowel stricture. Care should therefore be taken in those
with a history of colonic disease. Yadav et al. suggest
that radiological imaging and the patency device were
equally sensitive at detecting significant strictures,
although the majority of patients in the study under-
went CT rather than magnetic resonance imaging.1,24
Nevertheless other studies suggest that MRE is poorly
specific at detecting significant strictures.25
The study has limitations. This was a pragmatic
study of patients in routine clinical practice. Not all
patients had their blood or faecal tests within one
month of capsule endoscopy because of delays in per-
forming the procedure or a failure to provide a faecal
sample, which limits the comparison of biochemical
markers with capsule endoscopy. Not all centres were
able to provide reliable information about patients’ use
of non-steroidal anti-inflammatory drugs. The defini-
tion of active disease in PCE was arbitrary. It is possi-
ble that any identified inflammatory change was due to
active Crohn’s disease. On the other hand, there is sig-
nificant interobserver variability in lesion recognition26
and it is well established that minor abnormalities are
found in 10–15% of healthy volunteers.27,28 Therefore,
the definition of active disease in this study is aimed to
recognise at least mild active disease whilst minimising
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the chances of including what some might consider
variations of normal. Recent efforts to validate a scor-
ing system for PCE are welcome.29 Finally, clinicians
may have chosen a panenteric examination because of
a clinical suspicion of small bowel disease, thereby
making this a non-representative population; were
this the case, however, much of it was previously
unidentified as the panenteric study still had a major
impact on the diagnosis of L4 disease. Finally, assess-
ment of small and large bowel was variable in terms of
both completeness and proximity in time prior to PCE.
Incomplete examination and/or disease progression
might also explain why Montreal classification was
upstaged in some patients. However, it does also sug-
gest that while the current recommended panenteric
assessment is important, using two different tests1
may be impractical, perhaps due to patient inconve-
nience or clinician concern about the longer investiga-
tive pathway.
Conclusion
Capsule endoscopy provided an adequate single test,
panenteric examination for patients with Crohn’s dis-
ease leading to escalation in therapy in two-thirds of
those with active disease and with a 2.8% capsule
retention rate, both of which were resolved endoscop-
ically. One in five patients had disease proximal to the
terminal ileum and this was associated with escalation
of therapy. Clinical assessment was unreliable in assess-
ing disease activity and levels of CRP and FCP were
insensitive in detecting active disease. A PCE examina-
tion would be a suitable alternative to combined ileo-
colonoscopy and small bowel radiological imaging for
those with normal or indeterminate biomarker levels or
in whom raised levels might have an alternative expla-
nation. Controlled studies comparing the diagnostic
yield of PCE against ileocolonoscopy and MRE are
required to determine the utility of this approach.
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